On November 6, one of the universities which was granted federal land by the Morrill Acts of 1862 and 1890, Washington State University, announced that it would be partnering with Biopharmaceutical Research Company (BRC) to advance the research on medical marijuana and its impacts. BRC is a pharmaceutical company registered with the DEA.
Washington State University issued a press release saying that it partnered with the pharmaceutical company to launch an innovative study to evaluate marijuana and speed up the pace of marijuana research. The partnership will give the WSU scientists access to marijuana for research purposes while adhering to the federal regulations on cannabis.
The partnership will also enable WSU researchers to use BRC analytical services and knowledge to study the effect of marijuana on the physical and mental health of the consumers. It will also explore the impact of marijuana policies on public health and safety.
The Chair of Washington State University (WSU) Collaborative for Cannabis Policy, Research, and Outreach (CCPRO), Dr. Michael McDonnell, said that compared to other drugs, very little is known about the benefits and risks of marijuana. And for the researchers to obtain the pot they need to research its health effects on animals and humans, they must overcome several hurdles. Dr. McDonnell further said that WSU’s partnership with BRC would solve the problem of acquiring weed since BRC would provide them with marijuana for research purposes through federally compliant processes.
For the past 50-plus years, researchers have been allowed to source for marijuana for clinical trials from the University of Mississippi farm, which is federally approved and operated by the National Institute of Drug Abuse.
This is outright monopolization that leads to limited access to cannabis by the researchers, which then slows the progression of marijuana studies for years. In 2019, the federal government announced its plans to increase the number of producers cultivating marijuana for scientific research.
The collaboration between WSU and BRC is expected to help in addressing the importance of easy access to quality marijuana for research purposes; however, neither of the two entities is allowed to grow cannabis.
The Biopharmaceutical Research Company (BRC) CEO George Hodgin said that working with a reputable research institution such as WSU guarantees that they will be working with the best researchers in discovering the benefits of the pot products. It will also make sure that BRC is taking care of its responsibilities of ensuring public safety. Hodgin further said that the products have shown a great deal of potential by treating a variety of health conditions such as PTSD and chronic pain, yet the lack of federally-approved research in the U.S. is highly evident.
BRC applied for a cultivation permit in 2016, and if granted, the company would be in position to grow and produce marijuana and marijuana-derived products for research.
Analysts say this research is a welcome activity in the eyes of marijuana companies like Grapefruit Boulevard Investments Inc. (OTCQB: IGNG) and Dama Financial since the research findings will provide further proof of the therapeutic value of marijuana.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have a questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.